Terms: = Bone cancer AND SMO, Q99835, 6608, ENSG00000128602, SMOH, Gx AND Treatment
27 results:
1. Intraventricular SHH inhibition proves efficient in SHH medulloblastoma mouse model and prevents systemic side effects.
Kresbach C; Holst L; Schoof M; Leven T; Göbel C; Neyazi S; Tischendorf J; Loose C; Wrzeszcz A; Yorgan T; Rutkowski S; Schüller U
Neuro Oncol; 2024 Apr; 26(4):609-622. PubMed ID: 37767814
[TBL] [Abstract] [Full Text] [Related]
2. Rapid and Automated Semiconductor-Based Next-Generation Sequencing for Simultaneous Detection of Somatic DNA and RNA Aberrations in Myeloid Neoplasms.
Sande CM; Wu R; Yang G; Sussman RT; Bigdeli A; Rushton C; Chitturi A; Patel J; Szankasi P; Morrissette JJD; Lim MS; Elenitoba-Johnson KSJ
J Mol Diagn; 2023 Feb; 25(2):87-93. PubMed ID: 36503148
[TBL] [Abstract] [Full Text] [Related]
3. The PROTAC selectively degrading Bcl-x
Zhang S; Chen Y; Xu Z; Yang J; Sun R; Wang J; Sun Y; Jiang B; Yang X; Tan W
Theranostics; 2022; 12(17):7476-7490. PubMed ID: 36438482
[No Abstract] [Full Text] [Related]
4. A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base.
Martinez NL; Khanna O; Farrell CJ
Chin Clin Oncol; 2020 Dec; 9(6):75. PubMed ID: 32819111
[TBL] [Abstract] [Full Text] [Related]
5. The inhibition of microRNA-326 by SP1/HDAC1 contributes to proliferation and metastasis of osteosarcoma through promoting smo expression.
Huang JH; Xu Y; Lin FY
J Cell Mol Med; 2020 Sep; 24(18):10876-10888. PubMed ID: 32743904
[TBL] [Abstract] [Full Text] [Related]
6. miR-370 inhibits the angiogenic activity of endothelial cells by targeting smoothened (smo) and bone morphogenetic protein (BMP)-2.
Gu Y; Becker V; Zhao Y; Menger MD; Laschke MW
FASEB J; 2019 Jun; 33(6):7213-7224. PubMed ID: 30865837
[TBL] [Abstract] [Full Text] [Related]
7. The Mutational Profile of Unicystic Ameloblastoma.
Heikinheimo K; Huhtala JM; Thiel A; Kurppa KJ; Heikinheimo H; Kovac M; Kragelund C; Warfvinge G; Dawson H; Elenius K; Ristimäki A; Baumhoer D; Morgan PR
J Dent Res; 2019 Jan; 98(1):54-60. PubMed ID: 30216733
[TBL] [Abstract] [Full Text] [Related]
8. The identification of fibrosis-driving myofibroblast precursors reveals new therapeutic avenues in myelofibrosis.
Kramann R; Schneider RK
Blood; 2018 May; 131(19):2111-2119. PubMed ID: 29572380
[TBL] [Abstract] [Full Text] [Related]
9. Current treatment options for meningioma.
Apra C; Peyre M; Kalamarides M
Expert Rev Neurother; 2018 Mar; 18(3):241-249. PubMed ID: 29338455
[TBL] [Abstract] [Full Text] [Related]
10. Novel smoothened antagonists as anti-neoplastic agents for the treatment of osteosarcoma.
Bernardini G; Geminiani M; Gambassi S; Orlandini M; Petricci E; Marzocchi B; Laschi M; Taddei M; Manetti F; Santucci A
J Cell Physiol; 2018 Jun; 233(6):4961-4971. PubMed ID: 29215700
[TBL] [Abstract] [Full Text] [Related]
11. Frequent AKT1E17K mutations in skull base meningiomas are associated with mTOR and ERK1/2 activation and reduced time to tumor recurrence.
Yesilöz Ü; Kirches E; Hartmann C; Scholz J; Kropf S; Sahm F; Nakamura M; Mawrin C
Neuro Oncol; 2017 Aug; 19(8):1088-1096. PubMed ID: 28482067
[TBL] [Abstract] [Full Text] [Related]
12. Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment.
Lubik AA; Nouri M; Truong S; Ghaffari M; Adomat HH; Corey E; Cox ME; Li N; Guns ES; Yenki P; Pham S; Buttyan R
Int J Cancer; 2017 Jan; 140(2):358-369. PubMed ID: 27672740
[TBL] [Abstract] [Full Text] [Related]
13. Primary cilia are present on human blood and bone marrow cells and mediate Hedgehog signaling.
Singh M; Chaudhry P; Merchant AA
Exp Hematol; 2016 Dec; 44(12):1181-1187.e2. PubMed ID: 27612547
[TBL] [Abstract] [Full Text] [Related]
14. The human smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells.
Giordani G; Barraco M; Giangrande A; Martinelli G; Guadagnuolo V; Simonetti G; Perini G; Bernardoni R
Oncotarget; 2016 Aug; 7(34):55313-55327. PubMed ID: 27486815
[TBL] [Abstract] [Full Text] [Related]
15. BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response.
Tan S; Pollack JR; Kaplan MJ; Colevas AD; West RB
Oral Surg Oral Med Oral Pathol Oral Radiol; 2016 Jul; 122(1):e5-7. PubMed ID: 27209484
[TBL] [Abstract] [Full Text] [Related]
16. ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: identification of novel targets for concerted therapy concepts.
Kebenko M; Drenckhan A; Gros SJ; Jücker M; Grabinski N; Ewald F; Grottke A; Schultze A; Izbicki JR; Bokemeyer C; Wellbrock J; Fiedler W
Cell Signal; 2015 Feb; 27(2):373-81. PubMed ID: 25435423
[TBL] [Abstract] [Full Text] [Related]
17. Regulatory network of differentially expressed genes in metastatic osteosarcoma.
Yao P; Wang ZB; Ding YY; Ma JM; Hong T; Pan SN; Zhang J
Mol Med Rep; 2015 Mar; 11(3):2104-10. PubMed ID: 25434727
[TBL] [Abstract] [Full Text] [Related]
18. Identification of recurrent smo and BRAF mutations in ameloblastomas.
Sweeney RT; McClary AC; Myers BR; Biscocho J; Neahring L; Kwei KA; Qu K; Gong X; Ng T; Jones CD; Varma S; Odegaard JI; Sugiyama T; Koyota S; Rubin BP; Troxell ML; Pelham RJ; Zehnder JL; Beachy PA; Pollack JR; West RB
Nat Genet; 2014 Jul; 46(7):722-5. PubMed ID: 24859340
[TBL] [Abstract] [Full Text] [Related]
19. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract] [Full Text] [Related]
20. Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma.
Lo WW; Wunder JS; Dickson BC; Campbell V; McGovern K; Alman BA; Andrulis IL
Cancer; 2014 Feb; 120(4):537-47. PubMed ID: 24151134
[TBL] [Abstract] [Full Text] [Related]
[Next]
